Kevin Starr Net Worth

The estimated Net Worth of Kevin P Starr is at least $125 Milione dollars as of 16 June 2021. Mr. Starr owns over 17,842 units of Sage Therapeutics Inc stock worth over $2,401,736 and over the last 19 years he sold SAGE stock worth over $121,092,938. In addition, he makes $1,157,300 as Independent Chairman of the Board at Sage Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Starr SAGE stock SEC Form 4 insiders trading

Kevin has made over 17 trades of the Sage Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 17,842 units of SAGE stock worth $1,000,044 on 16 June 2021.

The largest trade he's ever made was selling 850,000 units of Sage Therapeutics Inc stock on 16 May 2016 worth over $26,562,500. On average, Kevin trades about 43,946 units every 40 days since 2005. As of 16 June 2021 he still owns at least 320,659 units of Sage Therapeutics Inc stock.

You can see the complete history of Mr. Starr stock trades at the bottom of the page.

Kevin Starr biography

Kevin P. Starr serves as Independent Chairman of the Board of the Company. From October 2011 to August 2013, he also served as our interim Chief Executive Officer. In 2007, Mr. Starr co-founded Third Rock Ventures, a venture capital firm where he remains a partner. From 2003 to 2007, Mr. Starr undertook a number of entrepreneurial endeavors in the life science and entertainment industries. From 2001 to 2002, Mr. Starr served as Chief Operating Officer of Millennium Pharmaceuticals, Inc., or Millenium. He also served as Millennium’s chief financial officer from 1998 to 2002. In the past five years, Mr. Starr has served on the board of directors of Alnylam Pharmaceuticals, Inc., Zafgen, Inc., MyoKardia, Inc., Agios Pharmaceuticals Inc., Global Blood Therapeutics, Inc., PanOptica, Inc. and Decibel Therapeutics, Inc. Mr. Starr received an M.S. in corporate finance from Boston College and a B.S./B.A. in mathematics and business from Colby College. Mr. Starr’s qualifications to serve on our Board of Directors include his executive management roles with responsibility over key financial and business planning functions and experience in the formation, development and business strategy of multiple start-up companies in the life sciences sector.

What is the salary of Kevin Starr?

As the Independent Chairman of the Board of Sage Therapeutics Inc, the total compensation of Kevin Starr at Sage Therapeutics Inc is $1,157,300. There are 9 executives at Sage Therapeutics Inc getting paid more, with Jeffrey Jonas having the highest compensation of $9,902,080.

What's Kevin Starr's mailing address?

Kevin's mailing address filed with the SEC is C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE, MA, 02142.

Insiders trading at Sage Therapeutics Inc

Over the last 10 years, insiders at Sage Therapeutics Inc have traded over $190,046,458 worth of Sage Therapeutics Inc stock and bought 150,092 units worth $6,260,297 . The most active insiders traders include Kevin P Starr, Robert Nelsen e Michael F Cola. On average, Sage Therapeutics Inc executives and independent directors trade stock every 32 days with the average trade being worth of $256,667. The most recent stock trade was executed by Kimi Iguchi on 2 January 2024, trading 1,642 units of SAGE stock currently worth $2,233.

What does Sage Therapeutics Inc do?

sage therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare cns disorders. our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. to achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. sage’s lead program, sage-547, is in clinical development for super-refractory status epilepticus (srse) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. sage’s robust chemistry platform has generated multiple new compounds that target the gabaa and nmda receptors, which have demonstrated preclinical activity. sage therapeutics is a private company launched in 2010 by an experienced team of r&d leaders, cns experts and investors.

Complete history of Mr. Starr stock trades at Agios Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Blueprint Medicines Corp, CytomX Therapeutics Inc, Editas Medicine Inc, Global Blood Therapeutics, MyoKardia, Sage Therapeutics Inc e Zafgen

Sage Therapeutics Inc executives and stock owners

Sage Therapeutics Inc executives and other stock owners filed with the SEC include:

• Jeffrey Jonas,
  President, Chief Executive Officer and Director
• Michael Cloonan,
  Chief Operating Officer
• Stephen Kanes,
  Chief Medical Officer
• Anne Cook,
  Senior Vice President, General Counsel, Secretary
• Kimi Iguchi,
  Chief Financial Officer, Treasurer
• Albert Robichaud,
  Chief Scientific Officer
• Elizabeth Barrett,
  Independent Director
• George Golumbeski,
  Independent Director
• Dr. Jeffrey M. Jonas,
  Chief Innovation Officer, Chair of the Science & Technology Forum and Director
• Kevin Starr,
  Independent Chairman of the Board
• Michael Cola,
  Independent Director
• James Frates,
  Independent Director
• Steven Paul,
  Independent Director
• Geno Germano,
  Independent Director
• Asha Nayak,
  Independent Director
• Anne Marie Cook,
  Sr. VP, Gen. Counsel & Sec.
• Dr. Albert J. Robichaud Ph.D.,
  Chief Scientific Officer
• Kimi E. Iguchi,
  CFO & Treasurer
• Barry E. Greene,
  Pres, CEO & Director
• Barry Greene,
  Director
• Dr. Jim Doherty Ph.D.,
  Chief Devel. Officer
• Dr. Amy Schacterle Ph.D.,
  Sr. VP of R&D Strategy and Bus. Management
• Erin E. Lanciani,
  Chief People & Experience Officer
• Helen Rubinstein,
  Investor Relations Officer
• Matt Lasmanis,
  Chief Technology & Innovation Officer
• Rock Ventures Ii, L.P.Third...,
  
• Howard H Pien,
  
• Thomas Anderson,
  See Remarks
• Robert Nelsen,
  Director
• Venture Fund Vii Lparch Ven...,
  
• Rock Ventures Ii, L.P.Third...,
  
• Laura Gault,
  Chief Medical Officer
• Jessica Federer,
  
• Christopher Benecchi,
  Chief Business Officer